Form 4: SpyGlass Pharma Director Dybbs Granted 27,400 Stock Options

SpyGlass Pharma, Inc. Director Michael Dybbs was granted 27,400 stock options with an exercise price of $16, vesting monthly over three years.

Summary

• Michael Dybbs, a Director of SpyGlass Pharma, Inc. (SGP), was granted 27,400 stock options.
• The options have an exercise price of $16 per share.
• The options will vest monthly over a three-year period, with 1/36th of the shares vesting each month following the grant date of February 5, 2026.
• Vesting is contingent upon Mr. Dybbs's continued service as an Outside Director, as defined in the Issuer's 2026 Equity Incentive Plan.
• The options expire on February 5, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as it aligns director incentives with long-term shareholder value, which is generally a healthy corporate governance practice.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The options provide a potential future upside for the director, reflecting confidence in the company's future value.

Risks

• The value of the options is subject to the future market price of SpyGlass Pharma, Inc. common stock.
• The options will only vest if Michael Dybbs continues to serve as an Outside Director through the applicable vesting dates.

Future Outlook

The stock options are subject to a three-year monthly vesting schedule, indicating a long-term incentive structure for the director, aligning their future compensation with the company's performance over this period.

Industry Context

Stock option grants are a standard component of executive and director compensation packages across various industries, particularly in growth-oriented companies like those in the pharma sector, to attract and retain talent and align interests with long-term shareholder value creation. StockSavvy.ai notes this is a routine compensation event.

Corporate Governance

Related Party Transactions

• The grant of 27,400 stock options to Michael Dybbs, a Director of SpyGlass Pharma, Inc., constitutes a related party transaction as it involves compensation to a key management personnel.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of director's interests with long-term company performance.

Next Steps

• Monthly vesting of 1/36th of the 27,400 shares subject to the option, commencing February 5, 2026, and continuing for 36 months.
• Michael Dybbs's continued service as an Outside Director for the options to vest.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a director as part of their compensation. While it indicates alignment of interests, it does not present new fundamental information significant enough to warrant a change in investment recommendation based solely on this filing. Investors should consider broader company performance and market conditions.

Keywords

SpyGlass Pharma, SGP, Michael Dybbs, Stock Options, Director Compensation, SEC Form 4, Equity Incentive Plan, Insider Transaction